Natural history of chronic hepatitis B: what exactly has REVEAL revealed? - Wikidata - awgldk - TriplyDB

Natural history of chronic hepatitis B: what exactly has REVEAL revealed?

Natural history of chronic hepatitis B: what exactly has REVEAL revealed?

http://www.wikidata.org/entity/Q38003214

about

Hepatitis B or C viral infection and risk of pancreatic cancer: a meta-analysis of observational studies Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog Therapy A current update on the rule of alternative and complementary medicine in the treatment of liver diseases Immune therapy for hepatitis B Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and C co-infected subjects in HBV endemic area: a community-based cohort study.Prognostic values of fluctuations in serum levels of alanine transaminase in inactive carrier state of HBV infection.Mushroom lectin overcomes hepatitis B virus tolerance via TLR6 signaling.Characteristics and management of patients with chronic hepatitis B in an integrated care setting Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis.Differential plasma microRNA profiles in HBeAg positive and HBeAg negative children with chronic hepatitis B Designing immune therapy for chronic hepatitis B.Hepatitis B virus genotype distribution and genotype-specific BCP/preCore substitutions in acute and chronic infections in Argentina.Changes in serum alanine aminotransferase levels in telbivudine versus lamivudine treatment for chronic hepatitis B: a meta-analysis.Children with Chronic Hepatitis B in the United States and Canada.Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA The Efficacy of Add-on Telbivudine Versus Switching to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Poor Responses to Adefovir Hepatitis-Associated Liver Cancer: Gaps and Opportunities to Improve Care.Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis.The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer.Female gender lost protective effect against disease progression in elderly patients with chronic hepatitis B.Why do I treat HBeAg-positive chronic hepatitis B patients with a nucleoside analogue.Entecavir for the treatment of patients with hepatitis B virus-related decompensated cirrhosis.Non-antigen-specific and antigen-specific immune therapies for chronic hepatitis B: evidences from laboratory benches and patient's bedsides.HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?Core promoter: a critical region where the hepatitis B virus makes decisions.Re-appraisal of old and new diagnostic tools in the current management of chronic hepatitis B.Novel insights into immunotherapy for hepatitis B patients.Clinical relevance of the study of hepatitis B virus covalently closed circular DNA.Prognosis and predictors of hepatocellular carcinoma in elderly patients infected with hepatitis B virus.Tolerability, pharmacokinetics and antiviral activity of rHSA/IFNα2a for the treatment of chronic hepatitis B infection.Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study.Familial clustering of hepatocellular carcinoma in HBsAg-positive patients in the United States.Favorable outcome of extended treatment with adding pegylated Interferonα-2a to entecavir for HBeAg-positive chronic hepatitis B: a case report.IL6 gene allele-specific C/EBPα-binding activity affects the development of HBV infection through modulation of Th17/Treg balance.High treatment modification rates with lamivudine therapy in HBV-infected patients with low baseline viremia and early virological response: A multicenter study.SNP rs7770370 in HLA-DPB1 loci as a major genetic determinant of response to booster hepatitis B vaccination: results of a genome-wide association study.Effect of hepatic steatosis on the progression of chronic hepatitis B: A prospective cohort and in vitro study.Association between extranodal natural killer/T-cell lymphoma and hepatitis B viral infection: a case-control study.Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B.Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma.

P2860

Q22305489-EF4AF825-25A1-41C9-8AB9-3E06D4B34D09 Q26740161-1A455F2E-B2DB-47DC-8DD3-FD8D15EA1C91 Q27012998-00EB04D9-57D3-458B-A70E-A4A237F56AB2 Q28078856-417DFF55-3EB0-4AB4-B54C-E141D4E0D7E8 Q31102359-6DAD6DC5-728C-4EF9-BD8F-613AF95A90D1 Q33580037-0059B97F-9E7D-4976-A022-A5A7F3394410 Q33918915-785570C8-ACD7-44AA-9428-E32D34217A35 Q34110725-45E8B27D-95E2-4C1C-8975-5D984CFC69ED Q34194760-706153FA-555E-455D-849D-AEA87878C40E Q34613446-7D29577B-27E7-451D-BBF8-F5505E24BF53 Q34825732-594B1817-F1C7-4BED-9CF8-10995A724942 Q35231194-76CCDD7A-D13A-47A1-A45E-2258D4B39B96 Q35562322-0D946148-2F95-4A04-BAF4-BAB1CE95DAD5 Q36327587-253E4820-1FFA-402E-9E9B-FD923946DB7B Q36686179-DFDD402D-7EB5-41B4-8974-0605E03797EB Q36805368-4DB9A003-0AFA-4FC0-9BA5-27C0F3E8B529 Q36871021-7D1C4A05-8853-427F-988A-48AD369AB2C1 Q37165101-52497D59-4AA2-40C5-A1A9-552F492CF43B Q37365328-706FCC64-C251-4FFE-B069-331A36DAA483 Q37444202-2A0BA1AC-873A-4829-BD00-3D9470760B04 Q38071399-2EC8EA5F-7ACC-4C88-8BB4-C9FAE29D62A6 Q38096069-21A1D871-5F27-4E46-895E-60A52149852A Q38098583-7F9736BF-B22D-492C-8C67-4D98E1C079FB Q38174258-ECA7F2C0-4E09-4FA8-82F4-DFC6BBA8407D Q38191563-2DDF38AC-5488-4DC8-9B05-52E967BE77E6 Q38237418-594A461F-5145-4725-AF4F-5FE0541B8101 Q38655228-B3474B02-A2C0-417B-BC44-94D3B74184B6 Q38685587-AE0AD6E2-5CC9-46EE-BB9D-E64AF39C038A Q40138677-2F99D435-7D3C-4C41-BEAC-0646B6D3172B Q40445667-59758128-5341-41AA-892C-A6B72FEBFA4D Q40687503-699D993A-3C7F-49BD-A2BE-74504A4EC509 Q40706745-AF78BB59-C21A-4663-A4F7-001B02CEB25B Q40832139-A1046A9E-AB34-4949-A6EC-704A8F78C1EC Q40961789-CE4AB33C-CA7C-4B32-8AC8-4A13DBC1ABB8 Q41467947-D434DE13-5055-430D-A57A-88D3760AB06D Q41666724-48471B00-D20D-427F-87E2-CFA3907A20C6 Q41709332-A3DDC9C0-7630-4FB4-860C-046C7A92C96C Q41721837-B863469F-5EC7-460C-820B-6BC0E2C9783B Q42194740-4D3E3D68-0A63-49E4-94B9-E0A9F2B2853C Q42255811-655DDCA9-B164-4788-A8A9-4BFEA11B0C58

P2860

Natural history of chronic hepatitis B: what exactly has REVEAL revealed?

http://www.wikidata.org/entity/Q38003214

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Natural history of chronic hepatitis B: what exactly has REVEAL revealed?

@en

type

label

Natural history of chronic hepatitis B: what exactly has REVEAL revealed?

@en

prefLabel

Natural history of chronic hepatitis B: what exactly has REVEAL revealed?

@en

P1433

Q38003214-CA74DA8E-1F82-4ADE-9049-9DF77015E66A

P1476

Q38003214-74CF7713-3CB5-4603-B397-B8068D9E02F2

P2093

Q38003214-35FDEC2A-213E-468D-8614-EB277C6E9F74

Q38003214-83D13B34-111A-40B4-8295-A676F746A809

Q38003214-D9071880-B199-4844-BCF5-60DC38F88131

P2860

Q38003214-05D85731-7D7A-4D1A-9C11-8B87A17D0415

Q38003214-0BE99641-934C-4E08-A1D1-6E91DA90017C

Q38003214-1013F0EC-211D-427E-87C5-6DF1BC086602

Q38003214-1B111350-8B53-4722-8C1A-8CAE1141F6C7

Q38003214-1C48D827-F27B-48CC-9C5D-60F88FACA20E

Q38003214-1CFD2AC9-334C-4EB3-9F6F-D9133C9FF4A2

Q38003214-210E5EA0-B1C2-449D-985A-E8C7E106AB00

Q38003214-29772389-21F6-4EB9-A490-DD466B1715DA

Q38003214-29BA518C-3965-42A0-9CD0-B82D59994B3C

Q38003214-2BAAD6CD-0D16-4D3F-99A6-2AED711EB934

P304

Q38003214-EE7990EC-5821-490F-BFD0-DA943BC683B7

P31

Q38003214-26FF90F7-40F2-4D84-8B44-41B7F41DFE80

P356

Q38003214-79738FFD-A3B2-4E0A-A945-DC566D287CEA

P433

Q38003214-4A78CC41-C5C4-459B-99E5-B168384BF468

P478

Q38003214-70DBE146-1A0C-48A4-A29B-B69454CD295E

P577

Q38003214-F8C692E6-DBBE-4E79-98E6-06404FC7ED68

P5875

Q38003214-3A0EFCD4-67F8-41B0-AA4C-0A59E6634929

P698

Q38003214-A05AA3C7-F65A-4352-9A5D-694D086A7794

P356

J.1478-3231.2012.02805.X

P1433

Liver International

P1476

Natural history of chronic hepatitis B: what exactly has REVEAL revealed?

@en

P2093

Chien-Jen Chen

http://www.w3.org/2001/XMLSchema#string

Hwai-I Yang

http://www.w3.org/2001/XMLSchema#string

Uchenna H Iloeje

http://www.w3.org/2001/XMLSchema#string

P2860

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

Global epidemiology of hepatitis B virus

Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study.

Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study

Management of hepatitis B: 2000--summary of a workshop.

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

Pancreatic involvement in chronic viral hepatitis.

Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature.

Seropositivity of hepatitis B e antigen and hepatocellular carcinoma.

P304

1333-1341

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1478-3231.2012.02805.X

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224283495

http://www.w3.org/2001/XMLSchema#string

P698

22510145

http://www.w3.org/2001/XMLSchema#string